| Emitents | Olainfarm, AS (213800WCG52W62ENOP27) |
| Veids | Finanšu pārskati |
| Valoda | EN |
| Statuss | Publicēts |
| Versija | |
| Datums | 2007-10-31 15:06:28 |
| Versijas komentārs | |
| Teksts |
JSC “Olainfarm” October 31st, 2007
JSC “Olainfarm” sales in nine months of 2007 exceeds that of 2006 by 24%
Profit and loss statement of JSC „Olainfarm“ for nine months of this year shows that company’s sales have grown by 24% while the net profit has grown by 61% compared to that of nine months of 2006.
Unaudited profit and loss statement of the parent company of JSC "Olainfarm" for nine months of 2007 shows that the company's sales were 13,17 million Lats (18, 74 mill. Euros), which is an increase by 24% compared to the sales in previous period last year when they amounted to 10, 59 million Lats (15,06 mill. Euros). Company's after tax profit in this period was 689 188 Lats (980 626 Euros), which represents an increase by 61% compared to the same indicator for nine months of 2006, when it was 427 354 Lats (608 070 Euros).
„Third quarter is a period of time which is the most vulnerable to seasonal fluctuations in sales, which also impacts the financial results. However, the third quarter is followed by forth which normally compensates the shortfalls of the third quarter, as sales of Olainfarm’s medicines and chemical products increase considerably,“ financial performance is commented by Olainfarm’s deputy CFO Salvis Lapinsh.
In 2007 JSC „Olainfarm“ plans to make 20.5 million Lats (29,2 million Euros) in sales and 1,68 million Lats (2.39 million Euros) in net profit. According to non-audited financial results of JSC „Olainfarm“ of 2006, total sales of the parent company were 15.56 million Lats (22.14 million Euro) and net profit reached 1.06 million Lats (1.51 million Euro).
Company's development strategy is targeted at development and production of products with higher value added as well as at strengthening of „Olainfarm's“ positions in both, existing and new markets. In 2007 the contracts have been signed on using the intellectual property on new original products. Within the coming years, among other products, five new particularly promising ones will be launched, those are - Meldonium, Olvazol, R-Fenibut, R-Fenotropil and Memantine, which will allow the company to increase its sales volumes for the next five years by at least 30% per annum every year.
Olaine, October 31st, 2007
Information prepared by:
Salvis Lapinsh
Deputy CFO, „Olainfarm“
mobile +37126448873
e-mail: slapinsh@olainfarm.lv |
| Pielikumi |
|